Ernexa Therapeutics (ERNAW) Income from Continuing Operations (2010 - 2026)
Ernexa Therapeutics' (ERNAW) quarterly Income from Continuing Operations came in at 5506000.0 in Q1 2026, up 32.87% YoY from 4143899.06 in Q1 2025, and down 266.58% on a QoQ basis from 1502000.0 in Q4 2025.
Powered by 
Analysis
Ernexa Therapeutics (ERNAW) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Ernexa Therapeutics (ERNAW) has 17 years of Income from Continuing Operations data on file, last reported at 5506000.0 in Q1 2026.
- Quarterly Income from Continuing Operations rose 32.87% year-over-year to 5506000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 11387000.0 (down 640.38% YoY) and the FY2025 annual result came in at 14084000.0, down 82947.06% from the prior year.
- Income from Continuing Operations fell to 5506000.0 in Q1 2026, from 1502000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 38797000.0 in Q4 2024 to a low of 26604000.0 in Q3 2024.
- A 5-year average of 2429705.88 and a median of 5506000.0 in 2026 frame the typical range for Income from Continuing Operations.
- The widest YoY moves for Income from Continuing Operations: up 730.54% in 2024, down 375.84% in 2024.
- Tracing ERNAW's Income from Continuing Operations over 5 years: stood at 20024000.0 in 2022, then sank by 130.73% to 6153000.0 in 2023, then soared by 730.54% to 38797000.0 in 2024, then plunged by 103.87% to 1502000.0 in 2025, then sank by 266.58% to 5506000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 5506000.0 (Q1 2026), 1502000.0 (Q4 2025), and 1240000.0 (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Ernexa Therapeutics | 67,312.70 | 67,312.70 | - | -4.01 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -4.01 Mn |
| Mar 31, 2026 | -5.51 Mn |
| Dec 31, 2025 | -1.50 Mn |
| Sep 30, 2025 | -1.24 Mn |
| Jun 30, 2025 | -3.14 Mn |
| Mar 31, 2025 | -8.20 Mn |
| Dec 31, 2024 | -5.78 Mn |
| Sep 30, 2024 | -26.60 Mn |
| Jun 30, 2024 | -5.53 Mn |
| Mar 31, 2024 | -6.65 Mn |
| Dec 31, 2023 | -6.15 Mn |
| Sep 30, 2023 | -5.59 Mn |
| Jun 30, 2023 | -4.51 Mn |
| Mar 31, 2023 | -5.42 Mn |
| Dec 31, 2022 | -4.49 Mn |
| Sep 30, 2022 | -7.32 Mn |
| Jun 30, 2022 | -3.40 Mn |
| Mar 31, 2022 | -9.38 Mn |
| Dec 31, 2021 | -10.15 Mn |
| Sep 30, 2021 | -85.99 Mn |